Fed. Circ. Questions Specificity Needed In Oxy IP Invalidation
By Dani Kass · April 8, 2026, 10:58 PM EDT
A Federal Circuit panel expressed frustration with attorneys from both Purdue Pharma LP and generic-drug maker Accord Healthcare Inc. Wednesday as it tried to navigate whether the Delaware district court order...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login